The EAN COVID-19 registry (ENERGY): An international instrument for surveillance of neurological complications in patients with COVID-19.

Beghi, Ettore; Helbok, Raimund; Crean, Michael; Chou, Sherry Hsiang-Yi; McNett, Molly; Moro, Elena; Bassetti, Claudio (2020). The EAN COVID-19 registry (ENERGY): An international instrument for surveillance of neurological complications in patients with COVID-19. (In Press). European journal of neurology Blackwell Science 10.1111/ene.14652

[img] Text
Beghi__2020__The_EAN_COVID_19_Registry.pdf - Accepted Version
Restricted to registered users only until 21 November 2021.
Available under License Publisher holds Copyright.

Download (7MB) | Request a copy

The COVID-19 pandemic is a global public health issue. Neurological complications have been reported in up to one-third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. community-based), the accuracy of the diagnostic approach, and the interpretation of the patients' complaints. Moreover, after recovering, patients can still experience neurological symptoms. To obtain a more precise picture of the neurological manifestations and outcome of the COVID-19 infection, an international registry (ENERGY) has been created by the European Academy of Neurology (EAN) in collaboration with European national neurological societies and the Neurocritical Care Society and Research Network (NCRN). ENERGY can be implemented as a stand-alone instrument for patients with suspected or confirmed COVID-19 patients AND neurological findings or as an addendum to an existing registry not targeting neurologic symptoms. Data are also collected to study the impact of neurological symptoms and neurological complications on outcomes. The variables included in the registry have been selected in the interest of most countries, to favour pooling with data from other sources, and to facilitate data collection even in resource-poor countries. Included are adults with suspected or confirmed COVID-19 infection, ascertained through neurological consultation, and providing informed consent. Key demographic and clinical findings are collected at registration. Patients are followed up to 12 months in search of incident neurological manifestations. As of August 19, 254 centres from 69 countries and four continents have made requests to join the study.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Bassetti, Claudio

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1351-5101

Publisher:

Blackwell Science

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

15 Dec 2020 17:37

Last Modified:

15 Dec 2020 17:37

Publisher DOI:

10.1111/ene.14652

PubMed ID:

33220127

Uncontrolled Keywords:

COVID-19 EAN SARS-CoV-2 complications neurological diseases outcome registry

BORIS DOI:

10.7892/boris.149344

URI:

https://boris.unibe.ch/id/eprint/149344

Actions (login required)

Edit item Edit item
Provide Feedback